Monday, 22 Jan 2018

You are here

Febuxostat Works in Early Gout But Fails to Protect from Xray Damage

Dalbeth and colleagues have published a novel report in Arthritis & Rheumatology, novel in that it is a trial of early gout patients that looks at clinical and radiographic outcomes. They showed that febuxostat improves magnetic resonance imaging (MRI) measures of synovitis and reduced gout flares, but failed to alter X-ray progression with 2 years follow-up. 

This double-blind, placebo-controlled study enrolled 314 early gout patients with serum uric acid [SUA] levels  ≥7.0 mg/dl. Patients were randomized to receive either placebo (PBO) or febuxostat 40 mg (that could be increased to 80 mg if the SUA level was ≥6.0 mg/dl on day 14.  Early gout was defined as only 1 or 2 prior gout flares.

The primary efficacy end point was the mean in the modified Sharp/van der Heijde erosion score for the index joint over 24 months.   They also looked at gout flares, and serum UA levels and the Rheumatoid Arthritis Magnetic Resonance Imaging Scoring (RAMRIS) scores for synovitis, erosion, and edema in the single affected joint.

On plain radiographs febuxostat did not alter joint erosion score over 2 years. In both treatment groups, the mean change from baseline to month 24 in the modified Sharp/van der Heijde erosion score for the single affected joint was minimal, with no between-group differences.

Febuxostat significantly improved the RAMRIS synovitis score at month 24 compared with placebo treatment (change from baseline -0.43 versus -0.07; P <0.001). 

Gout flares were signficantly fewer (than placebo) between months 6 and 14. Overall the incidence of gout flares was less with febuxostat (29.3% versus 41.4%; P < 0.05).  At months 12 and 24, febuxostat had more patients with a SUA < 6.0 mg/dl ( 64.3%, and 62.8%) compare to those on placebo (1.7%, and 5.7%) (P < 0.001).

Urate-lowering therapy with febuxostat improved magnetic resonance imaging-determined synovitis and reduced the incidence of gout flares in subjects with early gout.

The shortcomings of this trial included both a high dropout rate (only 57-59% completed 2 years) and the observation that flare rate benefits were only evident after the first 6 months.

The current trial points to several difficulties inherent in gout studies, including a nomadic (unreliable) study population, high flare rates with the iniation of urate-lowering therapy and the lack of an ideal endpoint. 

This study shows the SUA to be a modestly effective biomarker that can be achieved in the face of ongoing synovitis. 

This study proves the sensitivity of MRI, but shows surprisingly disappointing erosion outcomes with plain radiographs. 

Lastly, long-term trials of symptoms, joint integrity and comorbidities would be ideal in gout, but would appear to be difficult to do as a prospective randomized clinical trial.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

New BSR 2017 Gout Guidelines (Best of 2017)

The British Society for Rheumatology/British Health Professionals in Rheumatology first published a guideline for the management of gout in 2007. They have just updated and published their new guideline, largely because of new therapies, an increasing incidence of gout, low penetrance of urate lowering therapies, and the inability to achieve a target serum uric acid level.

Allopurinol Dose Escalation is Safe with Severe CKD

Hypertension, nephrolithiasis and chronic kidney disease (CKD) commonly associates with gout.  While there is a clear need to dose adjust NSAIDs and colchicine in those with CKD, there is some debate about the need to dose adjust when using allopurinol with CKD.

Risk of Gout Onset and Flare Linked to Urate Levels

Serum uric acid (SUA) levels are clearly linked to gout. Researchers from Harvard have systemically reviewed the literature to quantify the risk of onset and flare with varying levels of SUA.

Literature review identified 8 eligible articles reporting gout incidence and 18 articles reporting recurrent gout rates in the context of SUA levels.

Gout Associated with Work Absenteeism

Annals of Rheumatic Disease reports that gout is associated with higher work absenteeism and thus, increased costs for society due to productivity loss.

Using Swedish national and regional registry data from 2000 to 2012, researchers studied 4571 gout patients of working age, and compared them to 22 482 population controls and assessed patient characteristics, work-loss days (absenteeism), sick leave and disability.

Good News from ACR17 - Gout

The following is a collection of gout-specific mentions culled from RheumNow's coverage of the Annual ACR 2017 meeting in San Diego.